RxDoctor Payments Data

Tomas Brillantes, MD

Psychiatry · Kansas City, MONPI 1427130061

Payments from drug & device makers

$7,989in general payments, 2019–2025

Across 535 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$996
  • AbbVie$908
  • Vanda Pharmaceuticals Inc.$720
  • Johnson & Johnson$552
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$7,76397%
  • Education$2263%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,989 in reported general payments places this provider in the 85th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$5,200
Medicare patients
47
Services billed
95

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine54$341,435
Invega SustennaPaliperidone Palmitate98$282,781
Invega TrinzaPaliperidone Palmitate24$201,649
Abilify MaintenaAripiprazole47$126,188
RexultiBrexpiprazole49$74,855
TrintellixVortioxetine Hydrobromide102$53,427
Risperdal ConstaRisperidone Microspheres29$38,043
Clozapine246$18,004
VraylarCariprazine Hcl11$16,546
Divalproex Sodium ErDivalproex Sodium103$8,452
Aripiprazole53$7,414
Paliperidone ErPaliperidone53$6,731
Loreev XrLorazepam13$6,133
Trazodone Hcl283$5,303
Lurasidone Hcl39$3,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$552$522,473151 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,267$341,43554 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$996$201,04396 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$53,427102 claims
AbbVieVraylar$908$16,54611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →